NPR3

Summary

NPR3 (natriuretic peptide receptor 3, HGNC:7945) is a protein-coding gene on chromosome 5p13.3, encoding Atrial natriuretic peptide receptor 3 (P17342). Receptor for the natriuretic peptide hormones, binding with similar affinities atrial natriuretic peptide NPPA/ANP, brain natriuretic peptide NPPB/BNP, and C-type natriuretic peptide NPPC/CNP.

This gene encodes one of three natriuretic peptide receptors. Natriutetic peptides are small peptides which regulate blood volume and pressure, pulmonary hypertension, and cardiac function as well as some metabolic and growth processes. The product of this gene encodes a natriuretic peptide receptor responsible for clearing circulating and extracellular natriuretic peptides through endocytosis of the receptor. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 4883 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Boudin-Mortier syndrome (Strong, GenCC)
• GWAS associations: 107
• Clinical variants (ClinVar): 168 total — 1 pathogenic, 2 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001204375

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7945
Approved symbol	NPR3
Name	natriuretic peptide receptor 3
Location	5p13.3
Locus type	gene with protein product
Status	Approved
Aliases	GUCY2B, FLJ14054
Ensembl gene	ENSG00000113389
Ensembl biotype	protein_coding
OMIM	108962
Entrez	4883

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 retained_intron

ENST00000265074, ENST00000326958, ENST00000415167, ENST00000434067, ENST00000506712, ENST00000507141, ENST00000509104, ENST00000896209, ENST00000966542

RefSeq mRNA: 6 — MANE Select: NM_001204375 NM_000908, NM_001204375, NM_001204376, NM_001363652, NM_001364458, NM_001364460

CCDS: CCDS47196, CCDS56356, CCDS56357, CCDS87291

Canonical transcript exons

ENST00000265074 — 8 exons

Exon	Start	End
ENSE00001164694	32784796	32784883
ENSE00001917259	32711321	32712545
ENSE00001938989	32786234	32791720
ENSE00003467855	32774708	32774843
ENSE00003470871	32724698	32724820
ENSE00003573912	32738864	32739030
ENSE00003681582	32780722	32780816
ENSE00003790089	32782893	32783028

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 97.96.

FANTOM5 (CAGE): breadth broad, TPM avg 8.6255 / max 332.3969, expressed in 691 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56026	3.0844	432
56024	1.7816	448
56021	1.5994	463
56027	0.5657	226
56030	0.3952	191
56031	0.2629	114
56023	0.2597	140
56022	0.2169	106
56028	0.1961	58
56025	0.1554	83

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	97.96	gold quality
kidney epithelium	UBERON:0004819	96.70	gold quality
renal glomerulus	UBERON:0000074	96.61	gold quality
metanephric glomerulus	UBERON:0004736	96.19	gold quality
nephron tubule	UBERON:0001231	96.03	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.78	gold quality
myocardium	UBERON:0002349	93.66	gold quality
stromal cell of endometrium	CL:0002255	93.27	gold quality
blood vessel layer	UBERON:0004797	91.78	gold quality
tongue squamous epithelium	UBERON:0006919	91.30	gold quality
kidney	UBERON:0002113	91.27	gold quality
renal medulla	UBERON:0000362	90.95	gold quality
adult mammalian kidney	UBERON:0000082	90.81	gold quality
left ventricle myocardium	UBERON:0006566	89.99	gold quality
cortical plate	UBERON:0005343	89.76	gold quality
metanephros	UBERON:0000081	89.44	gold quality
visceral pleura	UBERON:0002401	89.20	gold quality
cortex of kidney	UBERON:0001225	87.70	gold quality
adult organism	UBERON:0007023	86.55	gold quality
lower lobe of lung	UBERON:0008949	85.98	gold quality
diaphragm	UBERON:0001103	84.96	gold quality
ascending aorta	UBERON:0001496	83.95	gold quality
thoracic aorta	UBERON:0001515	83.83	gold quality
lung	UBERON:0002048	83.73	gold quality
apex of heart	UBERON:0002098	83.35	gold quality
caput epididymis	UBERON:0004358	82.82	gold quality
squamous epithelium	UBERON:0006914	82.79	gold quality
cardiac atrium	UBERON:0002081	82.68	gold quality
esophagus squamous epithelium	UBERON:0006920	82.51	gold quality
skin of hip	UBERON:0001554	82.38	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	594.27
E-HCAD-56	yes	527.85
E-CURD-112	yes	190.84
E-HCAD-6	yes	41.06
E-ANND-3	yes	8.50
E-GEOD-100618	no	1040.70
E-CURD-10	no	67.38
E-HCAD-30	no	30.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

273 targeting NPR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117

Literature-anchored findings (GeneRIF, showing 40)

• protein structure: ligand binding domains (PMID:11556325)
• The novel Npr1 gene 3C variant and the Npr3 gene C(-55) allele are associated with hypertensive family history. (PMID:12872042)
• Atrial natriuretic paptide, purified from medium bathing cells expressing NPR-C, a receptor known to internalize natriuretic peptides, was degraded. (PMID:15459247)
• Novel six-nucleotide repeat polymorphism located 4 base pairs upstream of the major transcriptional initiation site. (PMID:15785005)
• model of hormone recognition and allosteric receptor activation revealed from structural studies of NPR-C [review] (PMID:15911071)
• discussion of NPR-C receptor coupling to different signaling pathways and their regulation [review] (PMID:15911072)
• A structural comparison of complexes of NPC-C with each NP hormones (ANP, BNP, and CNP)reveals that NPR-C uses a conformationally inflexible surface to bind three different, highly flexible, NP ligands. (PMID:16870210)
• The NPRC polymorphism is not an independent determinant of NP concentration in HF. (PMID:17890443)
• Ostn is a naturally occurring ligand of the NPR-C clearance receptor and may act to locally modulate the actions of the natriuretic system in bone by blocking the clearance action of NPR-C, thus locally elevating levels of C-type natriuretic peptide. (PMID:17951249)
• Genetic variation within the NPPA/NPPB and NPR3 genes is associated with risk of VnD after primary coronary artery bypass grafting (PMID:19326473)
• the NPR-C receptor is expressed in normal and neoplastic human alpha cells. (PMID:19352691)
• Data indicate that the familial ANP mutation associated with atrial fibrillation has only minor effects on natriuretic peptide receptor interactions but markedly modifies peptide proteolysis. (PMID:19458086)
• results suggest that variation in the C-type natriuretic peptide signaling pathway, involving the NPPC and NPR3 genes, plays an important role in determining human body height. (PMID:19570815)
• The mRNA levels of natriuretic peptide receptor-C appear to be increased in epicardial adipose tissue independent of their plasma levels in coronary artery disease. (PMID:20691218)
• The data indicates that ANP, BNP, and CNP and natriuretic peptide receptor transcripts are expressed and are functional in human lens epithelial cells. (PMID:20700369)
• integrative genomics approach to a large cohort of medulloblastomas has identified four disparate subgroups (NPR3)with distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome. (PMID:20823417)
• Data found a consistent and significant association between the rs2270915 polymorphism of the NPR3 gene and SBP in diabetic patients. This genetic variation may affect pressure response to changes in dietary sodium. (PMID:21464461)
• Results demonstrate the opposite effects of NPR-A and NPR-C in LPS-mediated endothelial permeability and lung injury. (PMID:22001395)
• Report the presence of CNP and its receptors, NPR2/3 in atherosclerotic plaques of human carotid artery, with increased expression of NPR3 in histologically unstable plaques. (PMID:22421372)
• polymorphisms or haplotype in NPR3 gene may influence the risk of ischemic stroke or hypertension independently in Chinese population. (PMID:22559095)
• a NPR3 promoter gene variant could have a role on cerebrovascular disease susceptibility (PMID:22995222)
• The significant change in NPR3 protein was observed for the Arg146 variant allozyme, with 20% of wild-type protein, primarily because of autophagy-dependent degradation. (PMID:23493048)
• Data show that natriuretic peptide receptor 3 (NPR3) single nucleotide polymorphism (SNP) is independently associated with diastolic dysfunction and does not appear to be related to alterations in circulating levels of natriuretic peptides. (PMID:24465655)
• Angiotensin II downregulates vascular smooth muscle cell NPR-C gene expression by destabilizing its mRNA. (PMID:25711724)
• Results from this study point to a role for miR-100 in the regulation of NPR3 expression, and suggest a possible therapeutic target for modulation of NP bioactivity in heart disease. (PMID:25736855)
• This study focused on the natriuretic peptide receptor C gene (NPR3). The correlation analysis between NPR3 and hypertension was replicated in 450 Chinese Dai and 484 Chinese Mongolian individuals. (PMID:26345810)
• The NPRC genetic variant,Rs1847018, is a genetic marker of essential hypertension. (PMID:26782497)
• NPR-C gene single nucleotide polymorphisms significantly contribute to CAD susceptibility in the Chinese Han population (PMID:27191271)
• This study suggested that NPR3 rs2270915 polymorphism was associated with decreased systolic blood pressure level marginally in essential hypertension patients in a Chinese Han population; the polymorphism may function through decreasing NPR3 mRNA expression and ANP level. (PMID:28497617)
• NPR3 expression is downregulated by MRCCAT1 in the in metastatic clear cell renal cell carcinoma. (PMID:28659173)
• study identifies novel, putative mechanisms for BP-associated variants at the NPR3 locus to elevate blood pressure. (PMID:29040610)
• loss of NPR-C reduces HRV due to perturbations in the regulation of the heart by the autonomic nervous system (PMID:29242602)
• It was the aim to investigate the expression of natriuretic peptide receptors NPR-A, NPR-B and NPR-C during adipocyte differentiation (AD), upon stimulation with fatty acids (FA), and in murine and human adipose tissue depots. (PMID:29409758)
• Suggest that pro-ANP/corin/NPR-C signaling is dominant in the vascular system in preeclampsia. (PMID:29523263)
• The levels of ANP, NPRA, IL-4 and GATA3 increased in peripheral blood of children with respiratory syncytial virus bronchiolitis. (PMID:30591105)
• A role of NPR-C mutation in pulmonary arterial hypertension is reviewed. (PMID:31234560)
• LncRNA FENDRR Upregulation Promotes Hepatic Carcinoma Cells Apoptosis by Targeting miR-362-5p Via NPR3 and p38-MAPK Pathway. (PMID:32251605)
• NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway. (PMID:34229087)
• Oxygen and steroids affect the regulatory role of natriuretic peptide receptor-C on surfactant secretion by type II cells. (PMID:34668435)
• Genetic evidence implicating natriuretic peptide receptor-3 in cardiovascular disease risk: a Mendelian randomization study. (PMID:37101178)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	npr3	ENSDARG00000035253
mus_musculus	Npr3	ENSMUSG00000022206
rattus_norvegicus	Npr3	ENSRNOG00000019184

Paralogs (17): GUCY1B1 (ENSG00000061918), GUCY2C (ENSG00000070019), ADCY2 (ENSG00000078295), GUCY2F (ENSG00000101890), ADCY7 (ENSG00000121281), ADCY4 (ENSG00000129467), GUCY2D (ENSG00000132518), ADCY3 (ENSG00000138031), GUCY1A2 (ENSG00000152402), ADCY8 (ENSG00000155897), NPR2 (ENSG00000159899), ADCY9 (ENSG00000162104), GUCY1A1 (ENSG00000164116), ADCY1 (ENSG00000164742), NPR1 (ENSG00000169418), ADCY5 (ENSG00000173175), ADCY6 (ENSG00000174233)

Protein

Protein identifiers

Atrial natriuretic peptide receptor 3 — P17342 (reviewed: P17342)

Alternative names: Atrial natriuretic peptide clearance receptor, Atrial natriuretic peptide receptor type C

All UniProt accessions (5): C9JK69, P17342, D6RDL8, H0Y9B9, Q60I31

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for the natriuretic peptide hormones, binding with similar affinities atrial natriuretic peptide NPPA/ANP, brain natriuretic peptide NPPB/BNP, and C-type natriuretic peptide NPPC/CNP. May function as a clearance receptor for NPPA, NPPB and NPPC, regulating their local concentrations and effects. Acts as a regulator of osteoblast differentiation and bone growth by binding to its ligand osteocrin, thereby preventing binding between NPR3/NPR-C and natriuretic peptides, leading to increase cGMP production.

Subunit / interactions. Homodimer; disulfide-linked. Dimers can also be formed through the C-terminal cysteine of isoform 2. Interacts with OSTN.

Subcellular location. Cell membrane.

Disease relevance. Boudin-Mortier syndrome (BOMOS) [MIM:619543] An autosomal recessive disorder characterized by tall stature, long digits, and extra epiphyses in the hands and feet. In addition, some patients show joint hypermobility and dilation of the aortic root. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Has low affinity for peptide hormones in the absence of bound chloride.

Similarity. Belongs to the ANF receptor family.

Isoforms (3)

UniProt ID	Names	Canonical?
P17342-1	1, NPR-C5	yes
P17342-2	2, NPR-C6
P17342-3	3

RefSeq proteins (6): NP_000899, NP_001191304, NP_001191305, NP_001350581, NP_001351387, NP_001351389 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001170	ANPR/GUC	Family
IPR001828	ANF_lig-bd_rcpt	Domain
IPR028082	Peripla_BP_I	Homologous_superfamily
IPR052612	ANP_Clearance_Receptor	Family

Pfam: PF01094

UniProt features (61 total): strand 19, helix 15, turn 7, glycosylation site 3, disulfide bond 3, splice variant 3, binding site 3, sequence variant 2, topological domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
1JDP	X-RAY DIFFRACTION	2
1YK0	X-RAY DIFFRACTION	2.4
1JDN	X-RAY DIFFRACTION	2.9
1YK1	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P17342-F1	84.99	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 106; 135; 136

Disulfide bonds (3): 108–136, 213–261, 473

Glycosylation sites (3): 394, 86, 293

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 339 (showing top): RNGTGGGC_UNKNOWN, VERHAAK_AML_WITH_NPM1_MUTATED_DN, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_BLOOD_PRESSURE, E2F4DP1_01, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, MODULE_64, LHX3_01, CHX10_01, SRF_Q5_01, NKX61_01, IRF7_01, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS

GO Biological Process (13): skeletal system development (GO:0001501), angiogenesis (GO:0001525), blood vessel remodeling (GO:0001974), osteoclast proliferation (GO:0002158), response to ischemia (GO:0002931), signal transduction (GO:0007165), regulation of blood pressure (GO:0008217), regulation of osteoblast proliferation (GO:0033688), positive regulation of urine volume (GO:0035810), negative regulation of cold-induced thermogenesis (GO:0120163), positive regulation of relaxation of smooth muscle (GO:1901082), cGMP biosynthetic process (GO:0006182), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (9): G protein-coupled peptide receptor activity (GO:0008528), natriuretic peptide receptor activity (GO:0016941), peptide hormone binding (GO:0017046), chloride ion binding (GO:0031404), peptide binding (GO:0042277), hormone binding (GO:0042562), protein homodimerization activity (GO:0042803), receptor decoy activity (GO:0140319), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), protein-containing complex (GO:0032991), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	3
G protein-coupled receptor activity	2
peptide receptor activity	2
system development	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
tissue remodeling	1
leukocyte proliferation	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
blood circulation	1
regulation of biological quality	1
osteoblast proliferation	1
regulation of cell population proliferation	1
regulation of urine volume	1
negative regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
relaxation of smooth muscle	1
positive regulation of relaxation of muscle	1
regulation of relaxation of smooth muscle	1
purine ribonucleotide biosynthetic process	1
cyclic nucleotide biosynthetic process	1
cGMP metabolic process	1
signal transduction	1
hormone binding	1
anion binding	1
identical protein binding	1
protein dimerization activity	1
molecular sequestering activity	1
membrane	1
cell periphery	1
cellular_component	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

724 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NPR3	NPPA	P01160	999
NPR3	GUCA2B	Q16661	996
NPR3	GUCA2A	Q02747	995
NPR3	NPPC	P23582	991
NPR3	NPPB	P16860	986
NPR3	NPTXR	O95502	817
NPR3	GUCY2C	P25092	793
NPR3	EMD	P50402	769
NPR3	NHERF4	Q86UT5	730
NPR3	OSTN	P61366	727
NPR3	ADGRD1	Q6QNK2	711
NPR3	ADGRG6	Q86SQ4	674
NPR3	SBF2	Q86WG5	673
NPR3	REN	P00797	650
NPR3	STH	Q8IWL8	641

IntAct

3 interactions, top by confidence:

A	B	Type	Score
NPR3	H1-1	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (21): NPR3 (Affinity Capture-RNA), HIST1H1A (Proximity Label-MS), NPPA (Reconstituted Complex), NPPB (Reconstituted Complex), NPPC (Reconstituted Complex), NPR3 (Affinity Capture-RNA), NPR3 (Proximity Label-MS), NPR3 (Proximity Label-MS), NPR3 (Proximity Label-MS), NPR3 (Proximity Label-MS), TPD52L2 (Cross-Linking-MS (XL-MS)), NPR3 (Co-fractionation), NPR3 (Co-fractionation), NPPA (Reconstituted Complex), NPPB (Reconstituted Complex)

ESM2 similar proteins: A8WPG9, A8XQC7, E7EAU8, E9NA96, G5ECB2, G5EFQ0, H2L002, N1NVB7, O02740, O16544, O62026, O62179, O75899, O88871, P10730, P11528, P16065, P17342, P34299, P41740, P51841, P51842, P55205, P70180, Q07553, Q09435, Q10028, Q10914, Q16478, Q19187, Q23310, Q23681, Q23682, Q26721, Q5SDA5, Q61625, Q61627, Q62640, Q68Y21, Q6TL19

Diamond homologs: P10730, P16066, P16067, P17342, P18293, P18910, P20594, P41740, P46197, P70180, Q6VVW5, Q86GV3, A0A0U1RPR8, A8WPG9, E7EAU8, H2L002, N1NVB7, O02298, O02740, O16715, O19179, O43306, O54865, O60266, O62179, O75343, O95622, P0A4Y1, P11528, P16065, P16068, P19686, P19687, P20595, P22717, P23897, P25092, P30803, P33402, P40144

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

168 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	63
Likely benign	60
Benign	30

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1285629	NM_001204375.2(NPR3):c.1524del (p.Lys507_Tyr508insTer)	Pathogenic
1285630	NM_001204375.2(NPR3):c.1088A>T (p.Asp363Val)	Likely pathogenic
4529510	NM_001204375.2(NPR3):c.1229del (p.Gly410fs)	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3521 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:32711975:T:C	F67L	0.999
5:32711977:T:A	F67L	0.999
5:32711977:T:G	F67L	0.999
5:32712173:G:A	G133R	0.999
5:32712173:G:C	G133R	0.999
5:32712174:G:A	G133E	0.999
5:32712248:G:T	G158W	0.999
5:32724709:T:C	C261R	0.999
5:32724711:T:G	C261W	0.999
5:32724731:G:C	R268P	0.999
5:32738875:T:A	W302R	0.999
5:32738875:T:C	W302R	0.999
5:32738877:G:C	W302C	0.999
5:32738877:G:T	W302C	0.999
5:32738927:T:C	L319P	0.999
5:32738974:T:C	F335L	0.999
5:32738975:T:G	F335C	0.999
5:32738976:T:A	F335L	0.999
5:32738976:T:G	F335L	0.999
5:32774735:G:C	D363H	0.999
5:32774736:A:C	D363A	0.999
5:32774736:A:T	D363V	0.999
5:32774738:G:C	A364P	0.999
5:32774763:T:C	L372P	0.999
5:32774843:G:C	G399R	0.999
5:32780755:G:A	G410E	0.999
5:32780755:G:T	G410V	0.999
5:32780761:G:C	R412P	0.999
5:32712165:T:C	L130P	0.998
5:32712173:G:T	G133W	0.998

dbSNP variants (sampled 300 via entrez): RS1000003665 (5:32764332 G>A,C), RS1000003704 (5:32750082 T>A,C), RS1000005457 (5:32722640 C>A), RS1000021590 (5:32709251 T>C), RS1000096057 (5:32753562 T>C), RS1000102691 (5:32780174 G>A,T), RS1000107968 (5:32750682 G>T), RS1000151360 (5:32716615 C>A,G,T), RS1000193081 (5:32758030 G>A), RS1000209944 (5:32725831 T>C), RS1000239117 (5:32710662 G>A,C), RS1000264224 (5:32750425 C>T), RS1000329331 (5:32738300 CT>C), RS1000341670 (5:32728423 A>G), RS1000359015 (5:32710920 G>A)

Disease associations

OMIM: gene MIM:108962 | disease phenotypes: MIM:619543

GenCC curated gene-disease

Disease	Classification	Inheritance
Boudin-Mortier syndrome	Strong	Autosomal recessive

Mondo (1): Boudin-Mortier syndrome (MONDO:0859194)

Orphanet (1): Pure or complex autosomal recessive spastic paraplegia (Orphanet:320346)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

107 associations (top):

Study	Trait	p-value
GCST000372_9	Height	3.000000e-07
GCST000431_2	Height	3.000000e-07
GCST000817_183	Height	2.000000e-21
GCST000817_6	Height	7.000000e-10
GCST001072_6	Blood pressure	2.000000e-08
GCST001074_1	Blood pressure	1.000000e-07
GCST001227_17	Systolic blood pressure	2.000000e-16
GCST001228_8	Diastolic blood pressure	9.000000e-12
GCST001235_14	Blood pressure	5.000000e-09
GCST001236_1	Blood pressure	4.000000e-09
GCST001238_1	Hypertension	3.000000e-10
GCST001330_2	Ovarian reserve	1.000000e-06
GCST001956_29	Height	1.000000e-10
GCST001956_48	Height	2.000000e-16
GCST002497_15	Blood pressure	2.000000e-07
GCST002497_16	Blood pressure	3.000000e-06
GCST002647_144	Height	4.000000e-18
GCST002647_75	Height	2.000000e-33
GCST003272_17	Systolic blood pressure	2.000000e-07
GCST003273_8	Diastolic blood pressure	3.000000e-06
GCST003275_7	Mean arterial pressure	3.000000e-08
GCST003275_9	Mean arterial pressure	3.000000e-07
GCST004063_69	Waist circumference adjusted for body mass index	6.000000e-10
GCST004063_71	Waist circumference adjusted for body mass index	1.000000e-11
GCST004067_129	Hip circumference adjusted for BMI	6.000000e-08
GCST004067_17	Hip circumference adjusted for BMI	6.000000e-13
GCST004067_211	Hip circumference adjusted for BMI	1.000000e-07
GCST004212_17	Height	4.000000e-08
GCST004279_8	Systolic blood pressure	2.000000e-06
GCST004562_184	Waist circumference adjusted for body mass index	4.000000e-08

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0006336	diastolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0006340	mean arterial pressure
EFO:0004770	ovarian reserve
EFO:0007789	BMI-adjusted waist circumference
EFO:0008039	BMI-adjusted hip circumference
EFO:0008002	physical activity measurement
EFO:0004329	alcohol drinking
EFO:0006527	smoking status measurement
EFO:0004327	electrocardiography
EFO:0008344	response to placebo
EFO:0600020	time to remission of COVID-19 symptoms
EFO:0004980	appendicular lean mass
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111337 (PROTEIN FAMILY), CHEMBL2247 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Transmembrane guanylyl cyclases

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
AP811	Binding	9.3	pKi
PL-3994	Agonist	8.15	pKi

ChEMBL bioactivities

47 potent at pChembl≥5 of 64 total, top 47 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.27	IC50	0.054	nM	CHEMBL4062470
10.27	IC50	0.054	nM	CHEMBL3349623
10.24	IC50	0.058	nM	CHEMBL4102000
10.23	Ki	0.059	nM	CHEMBL405854
10.10	IC50	0.079	nM	CHEMBL4060314
10.06	IC50	0.087	nM	CHEMBL4061379
10.00	Ki	0.1	nM	CHEMBL411542
10.00	IC50	0.099	nM	CHEMBL4099663
9.92	IC50	0.12	nM	CHEMBL4061318
9.92	IC50	0.12	nM	CHEMBL4076904
9.89	IC50	0.13	nM	CHEMBL4084160
9.85	IC50	0.14	nM	CHEMBL4089530
9.72	IC50	0.19	nM	CHEMBL4084171
9.60	Ki	0.25	nM	CHEMBL412913
9.60	Ki	0.25	nM	CHEMBL3349651
9.54	IC50	0.29	nM	CHEMBL413432
9.52	Ki	0.3	nM	CHEMBL294263
9.52	IC50	0.3	nM	CHEMBL4081715
9.44	IC50	0.36	nM	CHEMBL4071568
9.40	Ki	0.4	nM	CHEMBL61383
9.32	Ki	0.48	nM	CHEMBL58588
9.31	Ki	0.49	nM	CHEMBL264744
9.29	IC50	0.51	nM	CHEMBL4103929
9.28	IC50	0.52	nM	CHEMBL4088351
9.19	IC50	0.65	nM	CHEMBL4082715
9.03	IC50	0.93	nM	CHEMBL4062458
8.92	IC50	1.2	nM	CHEMBL4075426
8.82	IC50	1.5	nM	CHEMBL4098363
8.79	Ki	1.64	nM	CHEMBL414293
8.11	IC50	7.8	nM	CHEMBL4076901
7.96	IC50	11	nM	CHEMBL4087769
7.89	IC50	13	nM	CHEMBL4105659
7.89	IC50	13	nM	CHEMBL4076700
7.82	IC50	15	nM	CHEMBL4076102
7.66	IC50	22	nM	CHEMBL4092707
7.46	IC50	35	nM	CHEMBL4073884
7.44	IC50	36	nM	CHEMBL3349961
7.28	IC50	52	nM	CHEMBL3349622
7.27	IC50	54	nM	CHEMBL4097040
7.21	Ki	62	nM	CHEMBL59028
7.19	Ki	65	nM	CHEMBL304191
7.06	Ki	87	nM	CHEMBL415133
6.44	Ki	360	nM	CHEMBL412793
6.27	Ki	539	nM	CHEMBL435181
6.17	Ki	680	nM	CHEMBL294262
5.58	Ki	2600	nM	CHEMBL434023
5.54	Ki	2900	nM	CHEMBL61413

PubChem BioAssay actives

47 with measured affinity, of 190 total; 47 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	75468: Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)	ic50	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S,4R)-1-[2-[[(2R)-2-[[(2S)-3-cyclohexyl-2-[[(2R,4S)-4-hydroxy-1-[(2S)-3-hydroxy-2-[[(2R)-2-[(2-hydroxyacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-[(N’-methylcarbamimidoyl)amino]-1-[[(2S,3S)-3-methyl-1-(methylamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-1-[2-[[(2R)-2-[[(2S)-2-[[(2R)-1-[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-3-methyl-1-(methylamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-1-[2-[[(2R)-2-[[(2S)-2-[[(2R)-1-[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-1-[2-[[(2R)-2-[[(2S)-2-[[(2R)-1-[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-[(N’-methylcarbamimidoyl)amino]-1-[[(2S,3S)-3-methyl-1-(methylamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2R)-1-[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-1-[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S,4R)-1-[2-[[(2R)-2-[[(2S)-2-[[(2R,4S)-1-[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-[(N’-methylcarbamimidoyl)amino]-1-[[(2S,3S)-3-methyl-1-(methylamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-7,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0001	uM
(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4S,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52S)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0001	uM
(4S,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52S)-52-amino-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0001	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-1-[2-[[(2R)-2-[[(2S)-2-[[(2R)-1-[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0002	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	217856: Apparent binding constant against multiple binding sites	ki	0.0003	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0003	uM
(3S)-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-3-methyl-2-[[(2S)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]propanoyl]amino]pentanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4S,10S,16S,19R,22S,28S,31R,34S,37R,40S,49R,52S)-52-[[(2S)-2-[[(2R)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	75468: Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)	ic50	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4S,10R,16R,19S,22R,28R,31S,34S,37R,40S,49R,52S)-52-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid	147584: Apparent binding affinity for non-vasorelaxant receptor	ki	0.0003	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0004	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S)-2-methylbutyl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0004	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0005	uM
(4R,7S,13S,16S,19S,22S,25S,34S,37R)-37-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-34-benzyl-13,22-bis[(2S)-butan-2-yl]-19-(carboxymethyl)-16,25-bis[3-(diaminomethylideneamino)propyl]-7-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0005	uM
(3S)-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0005	uM
(4S,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52S)-52-amino-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31-[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22,40-dimethyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0005	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0006	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-acetamido-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0009	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0012	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0015	uM
(4S,7S,13S,16S,19S,22S,25S,34S,37S)-37-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-34-benzyl-13,22-bis[(2S)-butan-2-yl]-19-(carboxymethyl)-16,25-bis[3-(diaminomethylideneamino)propyl]-7-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0016	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0078	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0110	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0130	uM
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0130	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0150	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]acetyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0220	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0350	uM
(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoic acid	75468: Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)	ic50	0.0360	uM
2-[(4R,7S,10S,16S,19S,22S,25S,28S,37S,40R)-40-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-7-(3-amino-3-oxopropyl)-37-benzyl-16,25-bis[(2S)-butan-2-yl]-4-carbamoyl-19,28-bis[3-(diaminomethylideneamino)propyl]-10-methyl-6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38-dodecazacyclohentetracont-22-yl]acetic acid	75468: Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)	ic50	0.0520	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-acetamido-3-cyclohexylpropanoyl]amino]acetyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	1454179: Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubated for 2 hrs by top count method	ic50	0.0540	uM
N-[4-[2-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]phenyl]naphthalene-2-carboxamide	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0620	uM
(3S)-4-[[(2S)-1-[[(2S)-2-methylbutyl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S,3S)-3-methyl-2-[[(2S)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]propanoyl]amino]pentanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0650	uM
(4S,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52S)-52-amino-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22,34-dimethyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.0870	uM
(4S,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52S)-52-amino-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-34-(carboxymethyl)-31,40-bis[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-22,37-dimethyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.3600	uM
(3S)-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylpentyl]amino]-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[(2-phenylacetyl)amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.5390	uM
(3S)-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-3-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	0.6800	uM
(3S)-4-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	2.6000	uM
(3S)-3-[[(2S,3S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylpentyl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	37861: Displacement of [125I]- ANP from the Atrial Natriuretic Peptide Clearance Receptor.	ki	2.9000	uM

CTD chemical–gene interactions

82 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression, increases methylation	5
trichostatin A	affects cotreatment, increases expression	4
Tobacco Smoke Pollution	decreases expression, increases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, affects expression	3
Particulate Matter	affects cotreatment, decreases expression, increases abundance	3
bisphenol A	affects cotreatment, increases methylation, increases expression	2
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
(+)-JQ1 compound	decreases expression, increases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Doxorubicin	decreases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Silicon Dioxide	increases expression, decreases expression	2
Cyclosporine	decreases expression	2
FR900359	increases phosphorylation	1
sotorasib	affects cotreatment, decreases expression	1
geldanamycin	increases expression	1
2-methyl-4-isothiazolin-3-one	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
terbufos	increases methylation	1
dimethylselenide	decreases expression, increases oxidation, increases expression	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
didecyldimethylammonium	decreases expression	1
potassium chromate(VI)	decreases expression	1
cupric chloride	decreases expression	1

ChEMBL screening assays

22 unique, capped per target: 22 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL686062	Binding	Inhibitory activity against guanylate cyclase coupled receptor binding site in rabbit lung by using [125I]-ANP-(103-126)	Identification of structural requirements for analogues of atrial natriuretic peptide (ANP) to discriminate between ANP receptor subtypes. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0JC	Ubigene HeLa NPR3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.